PPT-2017 Measles & Rubella Initiative Partners’ Meeting

Opening Comments amp Perspectives Dr Suresh Jadhav Executive Director Serum Institute of India Pvt Ltd ssjseruminstitutecom We at Serum Institute of India Pvt Ltd feel proud of being a partner to PAHO WHO in achieving what is designated to be a historical achievement in eradication of Measles amp Rubella diseases from the Americas. Panel 01502. Vicki Stambos. The 13. th. Global Measles and Rubella Laboratory Network Meeting, Geneva, Switzerland, 29. th. June to 1. st. July 2015. Vicki Stambos. Accelerating Progress Towards Measles and Rubella Control and Elimination Meeting. WHO Western Pacific Region. UNICEF East Asia and Pacific Region. 1. 21 June 2016. Geneva, Switzerland. Regional Measles and Rubella Goals. 2003. : Measles elimination to be used to strengthen routine immunization . . Accelerating Progress towards Measles/Rubella Control and Elimination Goals Meeting. Geneva, Switzerland. June 19, 2016. Lance Rodewald. WHO China Country Office. Measles and Rubella Vaccination Schedule. Dr. Kimberly M. Thompson. Kid Risk, Inc., www.kidrisk.org. Topics. Context. I. ntegrated dynamic disease and economic . modeling. Discussion. http://www.wpro.who.int/vietnam/topics/immunization/measles_rubella/measles_rubella_big.png?ua=1. M&RI Partners’ Meeting. Michael F Thomas, . Director Vaccine Implementation. September 2017, Washington DC. Page: . 1. Reach every child. . Measles and Rubella support in Gavi countries by end of 2016. 2020. . Summary of the . Findings . and Implementation Status . Dr Kaushik . Banerjee. M&RI Partners' Meeting. Washington DC. 7 September 2017. 1. Objectives . of . the Review. To provide a candid review of progress . South East Asia Region. 1. 21 June 2016. Geneva, Switzerland. Regional Measles and Rubella Goals. 66th Meeting of the SEAR Regional Committee in September 2013 in New Delhi resolved . to adopt . the goal of . Dr. Kimberly M. Thompson. 11. th. Annual Measles and Rubella Partners Meeting. September 19, 2012. Acknowledgments. World Health Organization (WHO) Contract PO 200470477 APW . Radboud. . Duintjer. . Programme:Update. Stefano Malvolti . September 2015, Washington DC. Page: . 1. Reach every child. . MANY . REGIONS AT . RISK . / OFF . TRACK FROM MEASLES ELIMINATION GOALS. Source: . WHO . Source: WHO/UNICEF coverage estimates . Hotel Royal, Geneva, Switzerland, 21-23 June 2016. Paul Rota,. Measles, Mumps, Rubella, Herpesviruses Laboratory Branch, CDC . par1@cdc.gov. . National Center for Immunization & Respiratory Diseases. Measles. Etiology/agent factor . paramyxovirus.. morbillivirus. it is spherical in appearance ,measuring about 100~150nm in diameter . It has an outer envelope composed of M-protein, H-protein, F-protein, and internal core is RNA.. easily through the air, or through contact with uids in the nose or throat. The viruses can pass from person to person by coughing, sneezing, or sharing food or drinks. Children may become inf MEA R) VACCINE What is the measles, mump and rubella (MMR) vaccine? The MMR vaccine protects against three diseases: measles, mumps and rubella (german measles). The vaccine is approved by He alth C  .  . Frequently Asked Questions. For Use of Teachers. Government of India has decided to introduce. measles-rubella (MR). vaccine. . The vaccine will be launched through a campaign,. to be followed by inclusion of the MR vaccine.